Aardvark Therapeutics, Inc.

EFFECT effective

Aardvark Therapeutics, Inc. has received effectiveness for its S-3 registration statement, signaling the completion of its IPO process. The company, a clinical-stage biopharmaceutical firm, focuses on small-molecule therapeutics targeting metabolic diseases via TAS2R activation. Its lead candidate, ARD-101, is in a Phase 3 trial for Prader-Willi Syndrome (PWS) and a Phase 2 trial for hypothalamic obesity (HO). The S-3 filing aligns with prior IPO details, including underwriters and offering structure.

424B4 priced

Aardvark Therapeutics, Inc. is conducting its initial public offering (IPO) of 5,888,000 shares of common stock at $16.00 per share, with proceeds totaling $87.6 million. The company, a clinical-stage biopharmaceutical firm, focuses on developing small-molecule therapeutics targeting bitter taste receptors (TAS2Rs) for metabolic diseases. Its lead candidate, ARD-101, is in a Phase 3 trial for Prader-Willi Syndrome (PWS) and a Phase 2 trial for hypothalamic obesity (HO). The IPO follows regulatory approval, with shares set to list on Nasdaq under the ticker 'AARD.'

EFFECT effective

Aardvark Therapeutics, Inc. filed an S-1 registration statement for its initial public offering (IPO), effective February 12, 2025. This follows a prior 8-A12B filing from February 10, 2025, which registered common stock for listing on Nasdaq. The S-1 indicates the company is advancing toward public market access, with the registration statement incorporating detailed offering terms.

8-A12B effective

Aardvark Therapeutics, Inc. is registering its common stock for listing on the Nasdaq Stock Market LLC under the ticker symbol 'AARD' as part of its initial public offering (IPO). The filing confirms the registration of securities previously disclosed in the S-1/A registration statement, which outlined the company's plan to offer 5,888,000 shares of common stock at an anticipated price range of $16.00 to $18.00 per share. The IPO is contingent on Nasdaq listing approval, and the company has applied for a directed share program for insiders and affiliates.

S-1/A amended

Aardvark Therapeutics, Inc. is conducting an initial public offering (IPO) of 5,888,000 shares of common stock, with an anticipated price range of $16.00 to $18.00 per share. The company, a clinical-stage biopharmaceutical firm, focuses on developing small-molecule therapeutics targeting Bitter Taste Receptors (TAS2Rs) to treat metabolic diseases, particularly hyperphagia associated with Prader-Willi Syndrome (PWS) and hypothalamic obesity (HO). The current S-1/A filing includes updated details on clinical trials, including a Phase 3 trial for PWS (HERO trial) and a planned Phase 2 trial for HO (HONOR trial), as well as alignment with the FDA on trial design. The company remains an emerging growth company with no revenue to date.

S-1 filed

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics to activate innate homeostatic pathways for metabolic diseases. Its lead candidate, ARD-101, targets Bitter Taste Receptors (TAS2Rs) in the gut to modulate hunger signaling, with a Phase 3 trial underway for Prader-Willi Syndrome (PWS) and a planned Phase 2 trial for hypothalamic obesity (HO). The company is conducting its initial public offering (IPO) with an anticipated price range and Nasdaq listing, while disclosing risks related to clinical trials, regulatory approval, and reliance on a single product candidate.

DRS/A amended

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics to activate innate homeostatic pathways for metabolic diseases. Its lead candidate, ARD-101, targets gut-expressed Bitter Taste Receptors (TAS2Rs) to treat hyperphagia in Prader-Willi Syndrome (PWS) and hypothalamic obesity (HO). The company has initiated a Phase 3 trial (HERO) for PWS and plans a Phase 2 trial (HONOR) for HO, with ARD-101 showing tolerability and efficacy in earlier trials. A second program, ARD-201, combines TAS2R agonism with DPP-4 inhibition for obesity treatment.

DRS/A amended

Aardvark Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its clinical-stage biopharmaceutical pipeline. The company focuses on developing small-molecule therapeutics targeting Bitter Taste Receptors (TAS2Rs) to treat metabolic diseases, with its lead candidate ARD-101 in Phase 3 trials for Prader-Willi Syndrome (PWS) and Phase 2 trials for hypothalamic obesity (HO). The offering is contingent on Nasdaq listing approval, and the company highlights its emerging growth status and reduced reporting requirements.

DRS filed

Aardvark Therapeutics, Inc. is preparing for its initial public offering (IPO) by filing a Form S-1 registration statement. The company is a clinical-stage biopharmaceutical firm focused on developing small-molecule therapeutics targeting innate homeostatic pathways for metabolic diseases. Its lead candidate, ARD-101, is advancing toward a Phase 3 trial for hyperphagia associated with Prader-Willi Syndrome (PWS) and a Phase 2 trial for hypothalamic obesity (HO). The filing highlights collaboration with the FDA on trial design, potential for synergistic effects with GLP-1 therapies, and the company's status as an emerging growth company with reduced reporting requirements.